{
    "nctId": "NCT02528747",
    "briefTitle": "A Survey of Breast Cancer Patients With Metastatic Bone Disease Receiving Oral Ibandronate",
    "officialTitle": "A Multi-Center Observational Survey of Breast Cancer Patients With Metastatic Bone Disease Receiving Oral Ibandronate (BONDORAL)",
    "overallStatus": "COMPLETED",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 582,
    "primaryOutcomeMeasure": "Change in bone pain according to Visual Analog Scale (VAS) score",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Adults at least 18 years of age\n* Histologically confirmed breast cancer with bone metastasis\n* Receiving or indicated for the tablet formulation of ibandronate according to the summary of product characteristics (SmPC) and local labeling\n\nExclusion Criteria:\n\n* Contraindication to ibandronate according to SmPC\n* Ongoing participation in any trial evaluating the efficacy and/or safety of ibandronate",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}